Use of any alternative diluent is at your own discretion, and we are not responsible for any resulting changes in appearance or consistency, including cloudiness or gelling of the research product.* This combination preparation pairs CJC-1295 (No DAC) with Ipamorelin in a single 10mg lyophilized vial, providing researchers with a convenient dual-peptide formulation for studying synergistic growth hormone releasing mechanisms
Managing combined side effects Expect amplified GI effects: Both peptides slow gastric emptying Synergistic nausea (not just additive) Constipation very common Weeks 9-16 most challenging Nausea management protocol: Prevention from day 1 (ginger, small meals) Prescription anti-nausea (Zofran) essential Liquid nutrition if needed Slower titration if poorly tolerated Constipation prevention: 80-100 oz water daily Fiber 25-30g daily Magnesium citrate 300-500mg nightly MiraLAX as needed Nutrition maintenance: Protein shakes 2-3 daily (30-40g each) Target 60-80g protein minimum Multivitamin daily B12 supplementation When to reduce doses: Severe persistent nausea despite management Unable to maintain adequate nutrition Vomiting frequently Quality of life severely impacted See our common peptide mistakes beginners make to avoid errors
By attenuating ACSL-mediated FA activation, increased miR-19b-1 would lead to decreased FA oxidation, hence limiting maximal mitochondrial respiration capacity
PI3K, on the other hand, is responsible for the insulin-like actions of the hormones by activating Akt/protein-kinase B (PKB) and protein-kinase C (PKC), which subsequently leads to activation of p70 S6K and glycogen-synthase kinase 3[252]
